Cargando…
Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression
A characteristic of the three human-pathogenic Yersinia spp. (the plague agent Yersinia pestis and the enteropathogenic Yersinia pseudotuberculosis and Yersinia enterocolitica) is the expression of the virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced secr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194041/ https://www.ncbi.nlm.nih.gov/pubmed/12391013 http://dx.doi.org/10.1084/jem.20020908 |
_version_ | 1782147612265152512 |
---|---|
author | Sing, Andreas Rost, Dagmar Tvardovskaia, Natalia Roggenkamp, Andreas Wiedemann, Agnès Kirschning, Carsten J. Aepfelbacher, Martin Heesemann, Jürgen |
author_facet | Sing, Andreas Rost, Dagmar Tvardovskaia, Natalia Roggenkamp, Andreas Wiedemann, Agnès Kirschning, Carsten J. Aepfelbacher, Martin Heesemann, Jürgen |
author_sort | Sing, Andreas |
collection | PubMed |
description | A characteristic of the three human-pathogenic Yersinia spp. (the plague agent Yersinia pestis and the enteropathogenic Yersinia pseudotuberculosis and Yersinia enterocolitica) is the expression of the virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced secretion of yersinia antihost proteins and in evasion of the host's innate immune response. Here we report that recombinant LcrV signals in a CD14- and toll-like receptor 2 (TLR2)-dependent fashion leading to immunosuppression by interleukin 10 induction. The impact of this immunosuppressive effect for yersinia pathogenesis is underlined by the observation that TLR2-deficient mice are less susceptible to oral Y. enterocolitica infection than isogenic wild-type animals. In summary, these data demonstrate a new ligand specificity of TLR2, as LcrV is the first known secreted and nonlipidated virulence-associated protein of a Gram-negative bacterium using TLR2 for cell activation. We conclude that yersiniae might exploit host innate pattern recognition molecules and defense mechanisms to evade the host immune response. |
format | Text |
id | pubmed-2194041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21940412008-04-11 Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression Sing, Andreas Rost, Dagmar Tvardovskaia, Natalia Roggenkamp, Andreas Wiedemann, Agnès Kirschning, Carsten J. Aepfelbacher, Martin Heesemann, Jürgen J Exp Med Article A characteristic of the three human-pathogenic Yersinia spp. (the plague agent Yersinia pestis and the enteropathogenic Yersinia pseudotuberculosis and Yersinia enterocolitica) is the expression of the virulence (V)-antigen (LcrV). LcrV is a released protein which is involved in contact-induced secretion of yersinia antihost proteins and in evasion of the host's innate immune response. Here we report that recombinant LcrV signals in a CD14- and toll-like receptor 2 (TLR2)-dependent fashion leading to immunosuppression by interleukin 10 induction. The impact of this immunosuppressive effect for yersinia pathogenesis is underlined by the observation that TLR2-deficient mice are less susceptible to oral Y. enterocolitica infection than isogenic wild-type animals. In summary, these data demonstrate a new ligand specificity of TLR2, as LcrV is the first known secreted and nonlipidated virulence-associated protein of a Gram-negative bacterium using TLR2 for cell activation. We conclude that yersiniae might exploit host innate pattern recognition molecules and defense mechanisms to evade the host immune response. The Rockefeller University Press 2002-10-21 /pmc/articles/PMC2194041/ /pubmed/12391013 http://dx.doi.org/10.1084/jem.20020908 Text en Copyright © 2002, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Sing, Andreas Rost, Dagmar Tvardovskaia, Natalia Roggenkamp, Andreas Wiedemann, Agnès Kirschning, Carsten J. Aepfelbacher, Martin Heesemann, Jürgen Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression |
title | Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression |
title_full | Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression |
title_fullStr | Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression |
title_full_unstemmed | Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression |
title_short | Yersinia V–Antigen Exploits Toll-like Receptor 2 and CD14 for Interleukin 10–mediated Immunosuppression |
title_sort | yersinia v–antigen exploits toll-like receptor 2 and cd14 for interleukin 10–mediated immunosuppression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194041/ https://www.ncbi.nlm.nih.gov/pubmed/12391013 http://dx.doi.org/10.1084/jem.20020908 |
work_keys_str_mv | AT singandreas yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT rostdagmar yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT tvardovskaianatalia yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT roggenkampandreas yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT wiedemannagnes yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT kirschningcarstenj yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT aepfelbachermartin yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression AT heesemannjurgen yersiniavantigenexploitstolllikereceptor2andcd14forinterleukin10mediatedimmunosuppression |